

![]() |
Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials |
|
Authors | ![]() | |
Published in | RMD open. 2017, vol. 3, no. 2, e000496 | |
Abstract | Two randomised controlled trials, AMBITION (NCT00109408) and ADACTA (NCT01119859), showed tocilizumab (TCZ) monotherapy superior to methotrexate (MTX) and adalimumab (ADA) monotherapy, respectively, for improving rheumatoid arthritis (RA) disease activity. This study compared the benefit of TCZ versus MTX or ADA monotherapy for improving patient-reported outcomes (PROs) in patients with RA. | |
Identifiers | PMID: 28955499 | |
Full text | ||
Structures | ||
Research group | Mécanisme de l'inflammation articulaire (44) | |
Citation (ISO format) | STRAND, Vibeke et al. Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials. In: RMD Open, 2017, vol. 3, n° 2, p. e000496. doi: 10.1136/rmdopen-2017-000496 https://archive-ouverte.unige.ch/unige:110661 |